ObsEva (OBSV) Stock Price, News & Analysis

Company Overview

ObsEva SA (NASDAQ:OBSV) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapies in women’s reproductive health and pregnancy. The company focuses on addressing unmet needs in fertility, pregnancy maintenance, and gynecological conditions through precision targeting of hormonal pathways. ObsEva’s research programs are designed to improve outcomes for patients facing endometriosis, uterine fibroids, preterm birth risk, and in vitro fertilization (IVF) challenges.

The company’s lead candidate, nolasiban, is a selective oxytocin receptor antagonist being evaluated to enhance embryo implantation in IVF procedures. In parallel, ObsEva is advancing linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of uterine fibroids and endometriosis. Other pipeline assets include oral progesterone modulators aimed at preventing preterm labor and supporting early pregnancy. ObsEva has entered strategic alliances to support pivotal clinical trials and expedite regulatory submissions.

Headquartered in Geneva, Switzerland, with a U.S. presence in Boston, ObsEva maintains a global operational footprint that spans Europe, North America, and select emerging markets. The company collaborates with academic centers, clinical research organizations, and regional partners to facilitate patient recruitment, trial execution, and regulatory engagement. These collaborations support ObsEva’s goal of delivering data-driven solutions and ensuring broad access to its investigational therapies.

Founded in 2012, ObsEva is led by a management team and board of directors with extensive experience in reproductive science, endocrinology, and biopharmaceutical development. The company’s leadership combines deep scientific expertise with a track record of navigating complex clinical and regulatory pathways. ObsEva continues to pursue clinical milestones and strategic partnerships to bring its innovative reproductive health treatments to market and improve outcomes for women worldwide.

Key Stats

• Today's Range: $0.0005 to $0.0005
• 50-Day Range: N/A
• 52-Week Range: $0.08 to $2.14
• Volume: 110 shs
• Average Volume: 8.94 million shs
• Market Capitalization: $38.99 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OBSV Stock Analysis - Frequently Asked Questions

How have OBSV shares performed this year?

ObsEva's stock was trading at $0.0005 at the beginning of the year. Since then, OBSV stock has increased by 0.0% and is now trading at $0.0005.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23.

When did ObsEva IPO?

ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Allena Pharmaceuticals (ALNA), Bionano Genomics (BNGO) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OBSV
• CIK: 1685316
• Web: www.obseva.com
• Phone: (122) 552-3840
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -416.36%
• Return on Assets: -92.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 77,971,000
• Free Float: 66,743,000
• Market Cap: $38.99 thousand
• Optionable: Not Optionable
• Beta: 0.68